7th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 19-21, 2026 | Boston, Massachusetts, USA
Novel Psychoactive Substances and Emerging Drug Trends
Synthetic compounds that mimic traditional drugs but skirt legal frameworks are complicating addiction landscapes. The proliferation of novel psychoactive substances and emerging drug trends poses significant risks due to unpredictable potency and side effects. These substances often evade detection by standard drug screens, challenging clinicians during diagnosis and treatment. From synthetic cannabinoids to designer stimulants, their impact can be severe, leading to hospitalizations, psychosis, or fatal overdoses. Monitoring systems and toxicological advancements are now essential in keeping pace with new variants. Public awareness campaigns, rapid policy adaptation, and global data sharing are crucial to curbing the spread and harm of these unpredictable substances.
Frederick J Goldstein
Philadelphia College of Osteopathic Medicine, United States
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
John Michael Weber
Trauma Healed Life Coach, United States
Denis Larrivee
University of Navarra, Spain
Steve Cohen
Medvesta Hypnosis Healthcare, United States
Andrew Drasen
A Vision of Hope Media, United StatesSubmit your abstract Today
Title : The storm within: Neuropsychological insights into dysregulation and substance use in the adolescent brain
Ann Marie Leonard Zabel, Curry College, United States
Title : Integrating bibliopoetry therapy and digital health technologies for inflammation management: A neuropsychosomatic perspective
Nile Stanley, University of North Florida, United States
Title : Trauma: Till death do us part
John Michael Weber, Trauma Healed Life Coach, United States
Title : Addiction and the failure of meaning-forming
Jenni Guentcheva, GTI, United States
Title : Beating the blues today
Steve Cohen, Medvesta Hypnosis Healthcare, United States
Title : Reduction of chronic neuropathic pain by a THC-CBD combination capsule: ongoing pilot study
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States